MedTrace Logo

Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms

NCT06974058 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-12-19

No results posted yet for this study

Summary

This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nasafytol® (Quercetin/Curcumin Supplement)

Participants in this group will receive Nasafytol®, a combined dietary supplement containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules (single administration) twice a day for a duration of 8 weeks. The supplement is intended to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and overall quality of life.

Sponsors & Collaborators

  • Liaquat University of Medical & Health Sciences

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-22
Primary Completion
2025-11-18
Completion
2025-12-14

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06974058 on ClinicalTrials.gov